

THRU ONLINE FILING

August 24, 2019

BSE Limited
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023

The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051.

Re: Inspection of Company's formulations manufacturing unit situated at Piparia (Silvassa) by US FDA


This is to inform you that the US FDA conducted the inspection of the Company's Formulations manufacturing Unit situated at Piparia (Silvassa) from 19th August, 2019 to 23rd August, 2019. At the conclusion of the inspection, the US FDA issued a Form 483 with 3 (three) observations.

The Company shall be submitting its comprehensive response on these observations to the US FDA within the stipulated time frame.

The Company is committed to address these observations promptly.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish Kamath
Corporate Counsel & Company Secretary

Ipca Laboratories Ltd.
www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067, India | T: +91 22 6210 5000 F: +91 22 6210 5005
Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067, India | T: +91 22 6647 4444
E: ipca@ipca.com CIN: L24239MH1949PLC007837